Jefferies Maintains Buy on Insulet, Lowers Price Target to $190

Benzinga Newsdesk www.benzinga.com Negative 83.3%

Neg 83.3% Neu 0% Pos 0%

Jefferies analyst Matthew Taylor maintains Insulet (NASDAQ:PODD) with a Buy and lowers the price target from $275 to $190.